AstraZeneca Pharmaceuticals LP v. Amneal Pharmaceuticals LLC
1:15-cv-01139
Overview
Parties
Defendant
Amneal Pharmaceuticals LLC Operating Company
Represented By
2 Attorneys ListedPhillips, McLaughlin & Hall, P.A.
1200 N. Broom St, Wilmington, DE 19806
Phillips, Goldman, McLaughlin & Hall, P.A.
1200 North Broom St., Wilmington, DE 19806
Amneal Pharmaceuticals of New York, LLC Operating Company
Represented By
6 Attorneys ListedPhillips, McLaughlin & Hall, P.A.
1200 N. Broom St, Wilmington, DE 19806
Phillips, Goldman, McLaughlin & Hall, P.A.
1200 North Broom St., Wilmington, DE 19806
Plaintiff
Counter Claimant
Amneal Pharmaceuticals LLC Operating Company
Represented By
2 Attorneys ListedPhillips, McLaughlin & Hall, P.A.
1200 N. Broom St, Wilmington, DE 19806
Phillips, Goldman, McLaughlin & Hall, P.A.
1200 North Broom St., Wilmington, DE 19806
Amneal Pharmaceuticals of New York, LLC Operating Company
Represented By
6 Attorneys ListedPhillips, McLaughlin & Hall, P.A.
1200 N. Broom St, Wilmington, DE 19806
Phillips, Goldman, McLaughlin & Hall, P.A.
1200 North Broom St., Wilmington, DE 19806
Counter Defendant
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360° Radar 13 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| 🇺🇸 United States | US 6,872,700 B1 Asserted | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 7,153,825 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 7,399,489 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 7,407,932 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 2008024901 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 7,906,146 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 2011028179 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 2013016537 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 2015008030 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 11,638,099 P | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 13,201,799 P | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 17,536,500 P | US Continuation / Sibling | View Official Patent → |
| 🌐 PCT International (WIPO) | WO 2000041548 A2 | PCT World Application | View Official Patent → |
No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.
Patents Involved
There are 2 patents involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US6872700
Methods for glucagon suppression
|
Filed: 2000-01-14
Issued: 2005-03-29
|
Expired (Term Ended)
Expires: 2020-01-14
|
|
|
US6902744
Exendin agonist formulations and methods of administration thereof
|
Filed: 2000-01-14
Issued: 2005-06-07
|
Expired (Term Ended)
Expires: 2020-01-14
|
Patent Enforceability & Injunction Risk Assessment
Statutorily Barred — Patent expired. Under 35 U.S.C. § 283, courts cannot grant an injunction once a patent's term concludes. Litigation is restricted exclusively to past damages lookback.
Standard Statutory Term — No obviousness-type double patenting truncation noted.
Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).
Procedural Motions & Interlocutory Orders
Total Motions
21
Dispositive
0
Granted
0
Denied
0
Pending / Review
12
Motions by Category
Key Dispositive Motions & Rulings